The new advantages and perspectives of Latanoprost (Xalatan, Pfizer, USA) treatment in pseudoexfoliation glaucoma

Cover Page

Abstract


The purpose of this study was to compare Latanoprost and Timolol therapeutic activity in pseudoexfoliation glaucoma (PEG). Forty patients with moderate PEG aged from 62 до 78 were enrolled. The one year treatment included the instillation of one drop of Latanoprost 0.005 % once a day (20 patients) and Timololmaleat 0.5 % twice a day (20 patients). The IOP reduction rate in six months was 22 % and 17 % respectively for Latanoprost and Timolol and in twelve months — 17 % and 13 % respectively. The improvement of visual fields and morphometric parameters in Latanoprost group was observed in twelve months: the changes of perimetric indexes from –5.8 ± 0.23 dB to –4.6±1.18 dB (MD) and from 7.3 ± 0.19 dB to 3.8 ± 0.14 dB (PSD); the cup volume of optic nerve head was reduced significantly: from 0.31 ± 0.13 мм3 to 0.21 ± 0.15 мм3. In contrast to this in Timolol group the parameters have become worse: for rim volume this change was: from 0.25 ± 0.14 мм3 до 0.19 ± 0.08 мм3 and for perimetric indexMD: from 5.30.13 dB to 7.8 ± 0.35 dB. We concluded that Latanoprostmay be recommended as the first choice therapy in PEG.

Nataliya Ivanovna Kurysheva

Ophthalmological center, Federal Medical and Biological Agency of Russian Federation

Email: e-natalia@list.ru
MD, professor, head of diagnostic department

  1. Курышева Н. И., Деев А. И., Долгина Е. В. Псевдоэксофлиативная глаукома: особенности патогенеза и клинических проявлений // Глаукома: проблемы и решения. Всероссийская научно-практическая конференция. — 2004. — С. 102–105.
  2. Курышева Н.И, Южакова О. И., Трубилин В. Н., Капкова С. Г. Cелективная лазерная трабекулопластика в лечении псевдоэксфолиативной глаукомы // Глаукома. — 2006, № 1. — С. 20–24.
  3. Курышева Н. И., Ходак Н. А., Трубилин В. Н. Исследование нейропротекторного действия ксалатана в клинике // Глаукома. — 2008, № 2. — С. 35–40.
  4. Arciery E., Santana A., Rocha F. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudopfakia and aphakia: a 6-month randomized trial // Arch. of Ophthalmol. — 2005. — Vol. 123, N 2. — P. 186–192.
  5. Blika S., Saunte E. Timolol maleate in the treatnment of glaucoma simplex and glaucoma capsulare. A three-year follow up study // ActaOphthalmol. — 1982. — Vol. 60, N 6.– P. 967–976.
  6. Cellini M. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study // Ophthalmologica. — 2004. — Vol. 218, N 5. — P. 312–317.
  7. Drago F., Valzelli S., Emmi I., Marino A., Scalia C., Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo // Exp. Eye Res. — 2001. — Vol. 72, N 4. — P. 479–486.
  8. Kazakova D., Diestelhorst M., Schlotzer U. A histopathological study of iris changes in pseudoexfoliative glaucoma in patients treated with xalatan // World Glaucoma Congress. — Singapore, 2007. — Abstract Book. — P. 173.
  9. Konstas A., Hollo G., Akopov E., Teus M., Astakhov Y. Factors associated with long-term progression or stability in exfoliation glaucoma // Arch. Ophthalmol. — 2004. — Vol. 122, N 1. — P. 29–33.
  10. Konstas A., Mylopoulos N. Diurnal intraocular pressure reduction with latanoprost 0,005 % compared to timolol maleate 0,5 % as monotherapy in subjects with exfoliation glaucoma // Eye. — 2004. — Vol. 18, N 9. — P. 893–899.
  11. Konstas A., Koliakos G., Kanhardt as C. at al. Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humor of patients with exfoliative glaucoma // Exp. Eye Res. — 2006. — Konstas, A. G., 82, N 2. — P. 319–322.
  12. Konstas A., Kozobolis V. Efficacy and safety of latanoprost versus travaprost in exfoliative glaucoma patients // Ophthalmology. — 2007. — Vol. 114, N 4. — P. 653–657.
  13. Kudo H., Nakazawa T. Neuroprotective effect of latanoprost on rat retinal gangli cells // Graefe’s Arch. Clin. Exp. Ophthalmol. — 2006. — Vol. 244, N 8. — P. 1003–1009.
  14. Lindsey J., Kashiwagi K., Boyle D., Weinreb R. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells // Curr. Eye Res. — 1996. — Vol. 15, N 8. — P. 869–875.
  15. Odani N., Seike H., Kurashima H. Protective effect of latanoprost on glutamate-induced cytotoxicity // World Glaucoma Congress. — Singapore, July 18–21, 2007. — Abstract Book. — P. 184–185.
  16. Schlötzer-Scbrehardt U., Zenkel M., Küchle M., Naumann O. Role of transforming growth factor-β1 and its latent form binding protein in pseudoexfoliation syndrome // Exp. Eye Res. — 2001. — Vol. 73, N 6. — P. 765–780.

Views

Abstract - 383

PDF (Russian) - 213

PlumX


Copyright (c) 2013 Kurysheva N.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.